SOTYKTU Clinical, Regulatory And Commercial Intelligence Report 2026
Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "SOTYKTU Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive assessment of SOTYKTU (deucravacitinib) across approved and potential immune-mediated inflammatory disease indications. The analysis covers the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan, with historical data and SOTYKTU sales forecasts spanning 2020 to 2034.
Key Factors Driving SOTYKTU Market Growth
SOTYKTU is a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb. Its differentiated allosteric inhibition of TYK2, without direct inhibition of JAK1, JAK2, or JAK3 at therapeutic concentrations, supports its clinical and commercial positioning within the immunology market.
Long-term efficacy and safety data remain important drivers of physician confidence and patient adoption. Phase III and long-term extension findings indicate sustained PASI 75 response rates of approximately 67%-73% through five years, with PASI 90 responses of approximately 46% at year five. More than 5,000 patient-years of exposure have produced no new safety signals.
SOTYKTU also addresses a large and underpenetrated psoriasis market. Psoriasis affects approximately 100 million people worldwide, while many eligible patients remain undertreated or dissatisfied with existing options. Once-daily oral administration offers a commercial advantage for biologic-naive patients and individuals who prefer an oral therapy to injectable biologics. These factors may support earlier-line use, a broader prescriber base, and increased market penetration.
Recent SOTYKTU Development
In March 2026, Bristol Myers Squibb announced that the US Food and Drug Administration approved SOTYKTU for adults with active psoriatic arthritis. This milestone made SOTYKTU the first TYK2 inhibitor approved for psoriatic arthritis and expanded its commercial potential beyond plaque psoriasis.
Development continues across additional immune-mediated diseases, including systemic lupus erythematosus, Sjogren's syndrome, alopecia areata, Crohn's disease, cutaneous lupus erythematosus, discoid lupus erythematosus, and juvenile rheumatoid arthritis. The report evaluates these pipeline opportunities while accounting for clinical, regulatory, and competitive risks.
SOTYKTU Market Report Scope
- Current and forecasted SOTYKTU sales through 2034 across the 7MM. Market assessments for plaque psoriasis, psoriatic arthritis, and potential pipeline indications. Product analysis covering mechanism of action, dosage, administration, clinical development, and regulatory milestones. Historical performance, future revenue potential, peak sales estimates, and key forecast assumptions. SOTYKTU pricing, reimbursement, cost estimates, and regional variations. Patent analysis, anticipated generic entry, and potential effects on pricing and revenue. SWOT analysis, analyst perspectives, market positioning, growth drivers, and commercial barriers. Competitive intelligence covering marketed products, pipeline therapies, expected launches, and late-stage clinical programs. Commercial partnerships, licensing agreements, mergers and acquisitions, and other strategic developments.
Clinical and Competitive Assessment
The report reviews SOTYKTU clinical trials across approved and potential indications, including trial interventions, conditions, recruitment status, and expected completion dates. It also evaluates efficacy, safety, durability of response, and clinical differentiation relative to established systemic therapies and emerging competitors.
The competitive landscape analysis examines marketed treatments and pipeline candidates that may influence SOTYKTU market share. Particular attention is given to biologics, oral systemic therapies, and late-stage products targeting plaque psoriasis, psoriatic arthritis, lupus, inflammatory bowel disease, alopecia areata, and related immunological conditions.
SOTYKTU Market Outlook
The SOTYKTU market is expected to evolve through increased prescribing, sustained uptake in plaque psoriasis, expansion into psoriatic arthritis, and possible entry into additional indications. Oral convenience, selective TYK2 inhibition, durable clinical outcomes, and a growing body of long-term safety evidence may strengthen the product's competitive position.
Market growth could nevertheless be affected by pricing and reimbursement restrictions, competition from established biologics, emerging oral therapies, regulatory outcomes, and patent-related developments. The report assesses these variables to provide a balanced SOTYKTU revenue forecast through 2034.
Strategic Questions Addressed
- How is SOTYKTU positioned clinically and commercially across approved indications? What are the current and forecasted SOTYKTU sales in the United States, Europe, the United Kingdom, and Japan? Which assumptions support the SOTYKTU market forecast through 2034? How could indication expansion affect revenue, prescribing, and geographic penetration? Which marketed and late-stage therapies represent the strongest competitive threats? How do pricing, reimbursement, treatment duration, and regional cost differences influence adoption? What regulatory milestones, partnerships, licensing activities, and patent events could affect future performance?
The report supports pharmaceutical companies, investors, healthcare consultants, and other stakeholders seeking actionable intelligence on SOTYKTU market size, sales potential, clinical differentiation, competitive positioning, and long-term opportunities within the global immunology landscape.
Key Topics Covered
1. Report Introduction
2. SOTYKTU Overview in approved indications like Plaque psoriasis; as well as potential indication like Juvenile rheumatoid arthritis, Psoriasis, Sjogren's syndrome, Systemic lupus erythematosus, Alopecia areata, Crohn's disease, Cutaneous lupus erythematosus, and Discoid lupus erythematosus
2.1. Product Detail
2.2. SOTYKTU Clinical Development
2.2.1. SOTYKTU Clinical studies
2.2.2. SOTYKTU Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. SOTYKTU Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging SOTYKTU Therapies)
5. SOTYKTU Market Assessment
5.1. SOTYKTU Market Outlook in approved and potential indications
5.2. 7MM Analysis
5.2.1. SOTYKTU Market Size in the 7MM for approved and potential indications
5.3. Country-wise Market Analysis
5.3.1. SOTYKTU Market Size in the United States for approved and potential indications
5.3.2. SOTYKTU Market Size in Germany for approved and potential indications
5.3.3. SOTYKTU Market Size in France for approved and potential indications
5.3.4. SOTYKTU Market Size in Italy for approved and potential indications
5.3.5. SOTYKTU Market Size in Spain for approved and potential indications
5.3.6. SOTYKTU Market Size in the United Kingdom for approved and potential indications
5.3.7. SOTYKTU Market Size in Japan for approved and potential indications
6. SOTYKTU SWOT Analysis
7. Analyst's Views
8. Appendix
8.1. Bibliography
8.2. Report Methodology
List of Tables
Table 1: SOTYKTU, Clinical Trial Description, 2023
Table 2: SOTYKTU, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: SOTYKTU's pricing and cost Assumptions
Table 6: SOTYKTU's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: SOTYKTU Market Size in the US, in USD million (2020-2034)
Table 8: SOTYKTU Market Size in Germany, in USD million (2020-2034)
Table 9: SOTYKTU Market Size in France, in USD million (2020-2034)
Table 10: SOTYKTU Market Size in Italy, in USD million (2020-2034)
Table 11: SOTYKTU Market Size in Spain, in USD million (2020-2034)
Table 12: SOTYKTU Market Size in the UK, in USD million (2020-2034)
Table 13: SOTYKTU Market Size in Japan, in USD million (2020-2034)
List of Figures
Figure 1: SOTYKTU's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: SOTYKTU Market Size in the United States, USD million (2020-2034)
Figure 3: SOTYKTU Market Size in Germany, USD million (2020-2034)
Figure 4: SOTYKTU Market Size in France, USD million (2020-2034)
Figure 5: SOTYKTU Market Size in Italy, USD million (2020-2034)
Figure 6: SOTYKTU Market Size in Spain, USD million (2020-2034)
Figure 7: SOTYKTU Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: SOTYKTU Market Size in Japan, USD million (2020-2034)
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment